Autologous Concentrated Growth Factor Used to Treat Linear Scleroderma En Coup de Sabre: A Case Report

Abstract

Linear scleroderma en coup de sabre (LSCS) is a variant of localized scleroderma associated with band-like fibrotic lesions in the frontoparietal area. We report a case of LSCS in a woman who presented with progressive mild hyperchromia on the right side of her forehead, with dermal atrophy and hair and eyebrow loss. After the failure of conservative treatments, the patient responded dramatically to injection of autologous localized concentrated growth factor. After three treatments, the atrophy, stiffness, and angiotelectasis on the affected area had improved. No recurrence was detected 24 months after the last treatment. This is the first study describing the use of autologous concentrated growth factor injection to alleviate clinical symptoms of LSCS. This suggests that concentrated growth factor may be a treatment for LSCS in the clinic.

Adult-Onset Linear Morphea (en coupe de sabre) of the Face Successfully Treated with Photoactivated Low-Temperature Platelet-Rich Plasma: A Valid Therapeutic Option

“…Currently, cases of LM ( en coupe de sabre ) treated with PRP are underreported; to date, Belgaumkar et al [ 1 ] reported a case of a 24-year-old female patient with an en coup de sabre LM successfully treated with conventional PRP, while more recently, Wang et al [ 12 ] described the case of a 31-year-old woman with an LM of the face, successfully treated with an autologous growth factor concentration. In both cases, the patients showed a clear clinical improvement of the skin lesions without the onset of specific adverse reactions.…”

Disturbances of the stomatognathic system and possibilities of its correction in patients with craniofacial morphea

“…In the literature, we also find a single study describing the use of injections with the use of autologous concentrate of growth factors obtained from peripheral blood (CGF) in a patient suffering from morphea ECDS, who refused systemic treatment and in whom 6 months of topical treatment with Halometasone failed [54]. CGF is a carrier of growth factors (including VEGF -vascular endothelial growth factor, TGF-β -transforming growth factor, PDGF -platelet-derived growth factor, IGF -insulin-like growth factor) regulating proliferation, migration, remodelling of the intercellular matrix, differentiation and angiogenesis.…”

“…During 24 months of observation, there was no deterioration of the clinical situation, no side effects of the therapy were found. It should be noted, however, that all observations made were only subjective assessments made by the patient and the physician [54].…”